SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

Search

Smith & Nephew PLC

Atidarymo kaina

1,238 0.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1220

Max

1241.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

296M

Pardavimai

3B

P/E

Sektoriaus vid.

29.619

22.253

Pelnas, tenkantis vienai akcijai

0.429

Dividendų pajamingumas

3.04

Pelno marža

9.895

Darbuotojai

17,000

EBITDA

723M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+18.75% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.04%

4.31%

Kitas uždarbis

2026-03-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

11B

Ankstesnė atidarymo kaina

1237.76

Ankstesnė uždarymo kaina

1238

Smith & Nephew PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-03 23:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025-12-03 23:14; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025-12-03 22:01; UTC

Pagrindinės rinkos jėgos

Costco Wholesale Reports Higher Monthly Sales

2025-12-03 21:38; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025-12-03 23:59; UTC

Rinkos pokalbiai

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025-12-03 23:13; UTC

Rinkos pokalbiai

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025-12-03 23:10; UTC

Uždarbis

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025-12-03 23:08; UTC

Rinkos pokalbiai

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025-12-03 23:06; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025-12-03 22:59; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5M

2025-12-03 22:45; UTC

Rinkos pokalbiai

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025-12-03 22:20; UTC

Uždarbis

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025-12-03 22:19; UTC

Uždarbis

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025-12-03 22:17; UTC

Uždarbis

Salesforce Working to Add Voice to Agentforce, CEO Says

2025-12-03 22:16; UTC

Uždarbis

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025-12-03 22:15; UTC

Uždarbis

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025-12-03 22:10; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025-12-03 22:09; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025-12-03 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-03 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-03 21:49; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:23; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025-12-03 21:19; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:06; UTC

Uždarbis

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025-12-03 21:04; UTC

Uždarbis

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025-12-03 21:04; UTC

Uždarbis

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025-12-03 21:03; UTC

Uždarbis

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC Prognozė

Kainos tikslas

By TipRanks

18.75% į viršų

12 mėnesių prognozė

Vidutinis 1,464.78 GBX  18.75%

Aukščiausias 1,700 GBX

Žemiausias 1,018.01 GBX

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

6

Pirkti

3

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat